Bryan, tell us more about you and your background.
I am Bryan Porcello, in charge of operations management and finances at Kylys Aesthetics. I have a financial background, completing a Master in Finance in 2018 from the University of Lausanne and the Chartered Financial Analyst designation (CFA). I have nurtured my desire to manage a company during my first professional experience in Corporate Banking. Then, I co-founded a digital marketing company in 2020 and joined Kylys in 2021.
When was your company born and who is your core team?
Kylys Aesthetics develops the next generation of fillers based on Hyaluronic Acid. The core team is composed of Alexandre Porcello (CEO), Dr. Olivier Jordan (CSO) and myself (COO/CFO).
Bryan, talk about your technology..
Available commercial products of water-soluble polymers suffer from a very short body lifetime. Their excessively fast elimination is a clear drawback. Our Product HA Pearls is an entirely new biocompatible and biodegradable gel extremely easily injectable as a fluid gel at room temperature. It has an exceptional ability to form in the tissue, at body temperature, microgel structures providing unprecedented durable effect and absence of migration from the injection site. The microgel structures formed by HA Pearls upon exposition to body temperature act as barriers against degradation by endogenous enzymes or oxidation. Our technology fulfills medical, surgical and cosmetic needs in the fields of rheumatology, tissue regeneration, and aesthetic medicine. Based on our IP, we develop a portfolio of MedTech products. KYLYS’ technology is already protected by a patent.
How did you scale your company to the actual size?
We developed a prototype of our product thanks to Innosuisse funds from 2020 to 2021. We were able to structure our project with the help of coaches from different organizations promoting Swiss innovation. We joined the Fongit family at the beginning of the year, where we now have our offices and laboratory. We constantly hire interns to help us on the operations and scientific sides.
Our next step is to raise our first round of funds to perform all pre-clinical testing.